Multicenter randomized phase II study comparing docetaxel plus curcumin versus docetaxel plus placebo in first‐line treatment of metastatic castration‐resistant prostate cancer

Multicenter randomized phase II study comparing docetaxel plus curcumin versus docetaxel plus placebo in first‐line treatment of metastatic castration‐resistant prostate cancer

Abstract Background Metastatic castration‐resistant prostate cancer (mCRPC) patients have a poor prognosis, and curcumin is known to have antineoplastic properties. On the basis of previous phase I and phase II studies, we investigated whether the association of curcumin with docetaxel could improve...

Full description

Bibliographic Details
Main Authors: Judith Passildas‐Jahanmohan, Jean‐Christophe Eymard, Mélanie Pouget, Fabrice Kwiatkowski, Isabelle Van Praagh, Laurent Savareux, Marc Atger, Xavier Durando, Catherine Abrial, Damien Richard, Angeline Ginzac Couvé, Emilie Thivat, Brigitte Monange, Philippe Chollet, Hakim Mahammedi
Format: Article
Language:English
Published: Wiley 2021-04-01
Series:Cancer Medicine
Subjects:
chemotherapy
curcumin
docetaxel
metastatic castration‐resistant prostate cancer
phase II
randomized trial
Online Access:https://doi.org/10.1002/cam4.3806

Internet

https://doi.org/10.1002/cam4.3806

Similar Items